blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3842554

EP3842554 - BIOMARKERS FOR RESPONSE TO PI3K INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.10.2023
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  11.11.2022
FormerGrant of patent is intended
Status updated on  23.06.2022
FormerRequest for examination was made
Status updated on  07.01.2022
FormerThe application has been published
Status updated on  28.05.2021
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): BE, FR, GB, IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065 / US
[2021/26]
Inventor(s)01 / MOYNAHAN, Mary, Ellen
300 E 66TH ST
New York, NY 10065-6800 / US
02 / GASKELL, Alice
39-10 51st
St.Woodside, NY 11377 / US
 [2021/26]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2021/26]
Application number, filing date20201617.608.05.2015
[2021/26]
Priority number, dateUS201461991165P09.05.2014         Original published format: US 201461991165 P
US201461992173P12.05.2014         Original published format: US 201461992173 P
US201462004518P29.05.2014         Original published format: US 201462004518 P
[2021/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3842554
Date:30.06.2021
Language:EN
[2021/26]
Type: B1 Patent specification 
No.:EP3842554
Date:14.12.2022
Language:EN
[2022/50]
Search report(s)(Supplementary) European search report - dispatched on:EP06.05.2021
ClassificationIPC:C12Q1/6886
[2021/26]
CPC:
C12Q1/6886 (EP,US); A61K31/4196 (US); A61K31/566 (US);
C12Q1/68 (US); C12Q2600/106 (EP); C12Q2600/118 (US);
C12Q2600/156 (EP,US); C12Q2600/158 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/06]
Former [2021/26]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:BIOMARKER FÜR REAKTION AUF PI3K-HEMMER[2021/26]
English:BIOMARKERS FOR RESPONSE TO PI3K INHIBITORS[2021/26]
French:BIOMARQUEURS UTILISABLES POUR ÉVALUER LA RÉPONSE AUX INHIBITEURS DE LA PI3K[2021/26]
Examination procedure30.12.2021Amendment by applicant (claims and/or description)
30.12.2021Examination requested  [2022/06]
30.12.2021Date on which the examining division has become responsible
24.06.2022Communication of intention to grant the patent
04.11.2022Fee for grant paid
04.11.2022Fee for publishing/printing paid
04.11.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15789311.6  / EP3140427
Opposition(s)15.09.2023No opposition filed within time limit [2023/47]
Fees paidRenewal fee
12.02.2021Renewal fee patent year 03
12.02.2021Renewal fee patent year 04
12.02.2021Renewal fee patent year 05
12.02.2021Renewal fee patent year 06
13.05.2021Renewal fee patent year 07
18.03.2022Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
IT14.12.2022
LT14.12.2022
LV14.12.2022
MC14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SI14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
GB08.05.2023
IE08.05.2023
LU08.05.2023
BE31.05.2023
CH31.05.2023
FR31.05.2023
LI31.05.2023
[2024/26]
Former [2024/21]AL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
MC14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SI14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
IE08.05.2023
LU08.05.2023
CH31.05.2023
LI31.05.2023
Former [2024/09]AL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
MC14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SI14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
LU08.05.2023
CH31.05.2023
LI31.05.2023
Former [2024/08]AL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
MC14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SI14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
LU08.05.2023
Former [2023/51]AL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SI14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
Former [2023/46]AL14.12.2022
AT14.12.2022
CZ14.12.2022
DK14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
Former [2023/39]AL14.12.2022
AT14.12.2022
CZ14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
IS14.04.2023
PT14.04.2023
Former [2023/38]AL14.12.2022
AT14.12.2022
CZ14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
PL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SK14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
PT14.04.2023
Former [2023/37]AL14.12.2022
AT14.12.2022
CZ14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
PT14.04.2023
Former [2023/35]AT14.12.2022
CZ14.12.2022
EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
RO14.12.2022
RS14.12.2022
SE14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
PT14.04.2023
Former [2023/34]EE14.12.2022
ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
RS14.12.2022
SE14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
PT14.04.2023
Former [2023/33]ES14.12.2022
FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
RS14.12.2022
SE14.12.2022
SM14.12.2022
NO14.03.2023
GR15.03.2023
Former [2023/29]FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
NL14.12.2022
RS14.12.2022
SE14.12.2022
NO14.03.2023
GR15.03.2023
Former [2023/25]FI14.12.2022
HR14.12.2022
LT14.12.2022
LV14.12.2022
RS14.12.2022
SE14.12.2022
NO14.03.2023
GR15.03.2023
Former [2023/23]FI14.12.2022
LT14.12.2022
LV14.12.2022
SE14.12.2022
NO14.03.2023
GR15.03.2023
Former [2023/22]FI14.12.2022
LT14.12.2022
SE14.12.2022
NO14.03.2023
Former [2023/20]LT14.12.2022
NO14.03.2023
Documents cited:Search[Y]WO2013015833  (GENENTECH INC [US], et al) [Y] 1-15 * the whole document * * Fig. 5; p. 7, ll. 4-8; p. 20, ll. 9-23; p. 33, l. 28 - p. 35, l. 24 *;
 [Y]WO2013144249  (NOVARTIS AG [CH], et al) [Y] 1-15 * the whole document * * p. 3, first par. *;
 [XY]US2014044706  (BELVIN MARCIA [US], et al) [X] 1,2,5-13,15 * the whole document * * par. 9, 13, 20, 35-39, 47, 48, 125, 171-177, claims 1, 28, 44, 49, 51, 59, Fig. 1-4 * [Y] 3,4,14;
 [X]  - Mary Ellen Moynahan, "Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3Kalpha inhibitor plus letrozole (L) or exemestane (E)", Journal of Clinical Oncology, vol. 32, no. 15, doi:10.1200/jco.2014.32.15_suppl.517, (20140501), URL: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.517, (20171013), XP002774657 [X] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1200/jco.2014.32.15_suppl.517
 [Y]  - JEFFREY A ENGELMAN ET AL, "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers", NATURE MEDICINE, (20081201), vol. 14, no. 12, doi:10.1038/nm.1890, ISSN 1078-8956, pages 1351 - 1356, XP055012919 [Y] 1-15 * the whole document * * abstract, Fig. 2 *

DOI:   http://dx.doi.org/10.1038/nm.1890
 [Y]  - ISAKOFF STEVEN J ET AL, "Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20051201), vol. 65, no. 23, doi:10.1158/0008-5472.CAN-05-2612, ISSN 0008-5472, pages 10992 - 11000, XP002534440 [Y] 1-15 * the whole document * * abstract, p. 10995, Fig. 2B *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-05-2612
 [Y]  - ELKABETS M ET AL, "MTORC1 inhibition is required for sensitivity to PI3K p110[alpha] inhibitors in PIK3CA-mutant breast cancer", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (A A A S), US, (20130731), vol. 5, no. 196, doi:10.1126/SCITRANSLMED.3005747, ISSN 1946-6234, pages 1 - 15, XP008169805 [Y] 1-15 * the whole document * * Fig. 1 *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3005747
 [Y]  - SAUVEUR-MICHEL MAIRA ET AL, "PI3K inhibitors for cancer treatment: where do we stand?", BIOCHEMICAL SOCIETY TRANSACTIONS, (20090201), vol. 37, no. 1, doi:10.1042/BST0370265, ISSN 0300-5127, page 265, XP055077107 [Y] 1-15 * the whole document * * Table 1 *

DOI:   http://dx.doi.org/10.1042/BST0370265
by applicantWO2012052745
 WO2013049581
    - "NCBI", Database accession no. GI: 126302584
    - SAMUELS et al., Science, (20040000), vol. 304, no. 5670, page 554
    - CAMPBELL et al., Cancer Res., (20040000), vol. 64, no. 21, pages 7678 - 7681
    - LEE et al., Oncogene, (20050000), vol. 24, pages 1477 - 1480
    - CIZKOVA et al., Breast Cancer Res., (20120000), vol. 14, no. 1, page R28
    - BACHMAN et al., Cancer Biol. Ther., (20040000), vol. 3, no. 8, pages 772 - 775
    - KARAKAS et al., British Journal of Cancer, (20060000), vol. 94, pages 455 - 459
    - SCHMIDT-KITTLER et al., Oncotarget, (20100000), vol. 1, no. 5, pages 339 - 348
    - WU et al., Med. Chem. Comm., (20120000), vol. 3, pages 659 - 662
    - HAYAKAWA et al., Bioorg. Med. Chem., (20070000), vol. 15, no. 17, pages 5837 - 5844
    - P. SUNNUCKS et al., Genetics, (19960000), vol. 144, pages 747 - 756
    - S. M. ALJANABII. MARTINEZ, Nucl. Acids Res., (19970000), vol. 25, pages 4692 - 4693
    - S. GUSTINCICH et al., BioTechniques, (19910000), vol. 11, pages 298 - 302
    - J. B. W. HAMMOND et al., Biochemistry, (19960000), vol. 240, pages 298 - 300
    - FORSHEW et al., Sci. Transl. Med., (20120000), vol. 4, no. 136, page 136
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.